HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Estee Lauder board changes

This article was originally published in The Rose Sheet

Executive Summary

Ronald S. Lauder will retire from The Estee Lauder Companies board of directors, the beauty firm announces July 14. Ronald Lauder has served on the board since 1968. He will continue to serve as chairman of Clinique Laboratories and as an officer of The Estee Lauder Companies. Ronald Lauder's daughter, Jane Lauder, will fill the vacancy on the board. Previously senior VP-global marketing for Clinique, she was named senior VP/general manager of Origins last year 1("The Rose Sheet" June 9, 2008). "Jane's innovative marketing sense, longstanding commitment to our company and proven talent has earned her the respect of our directors. She has a deep understanding of our business and the family values upon which our company has been built," says William P. Lauder, executive chairman of The Estee Lauder Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016289

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel